Personalis, Inc.

Personalis, Inc. is partnering with biopharma to develop and commercialize the next generation of cancer immunotherapies.We provide advanced genomic sequencing and analytics for immuno-oncology. Our patented ACE (Accuracy and Content Enhanced) Technology forms the foundation of all Personalis products and makes it possible for us to achieve augmented coverage of difficult-to-sequence genomic regions often missed with the use of conventional sequencing techniques, for more comprehensive and accurate genomic data. ACE ImmunoID, our universal platform for immuno-oncology, combines augmented whole exome and transcriptome assays with analytics that capture neoantigens, elucidate the tumor microenviroment, and identify mechanisms of tumor escape. The company’s Clinical Laboratory is GxP aligned as well as CLIA’88 and CAP accredited. To learn more, visit us at www.personalis.com and follow us on Twitter @personalisinc.